Comparative Pharmacology
Head-to-head clinical analysis: PCE versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PCE versus WYAMYCIN E.
PCE vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PCE (erythromycin) binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptides.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Erythromycin ethylsuccinate (PCE) typical adult dose: 400 mg orally every 6 hours or 800 mg orally every 12 hours. Maximum 4 g/day.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to 7-10 hours in renal impairment (CrCl <30 mL/min).
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Primarily renal (about 70-80% as unchanged drug and metabolites via glomerular filtration and tubular secretion); minor biliary/fecal elimination (10-15%).
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic